Mycobacterium susceptibility to ivermectin by inhibition of eccD3, an ESX-3 secretion system component.
Fig 8
Growth curve of M. smegmatis PLJR962-eccD3-gRNA strain with linezolid and rifampicin.
Growth curves of M. smegmatis mc2 155 wild type strain (diamonds, inner graph a and b), M. smegmatis PLJR962-eccD3-gRNA strain (circles) (a) and (b) without (gray line) and with (black line) ATc 0.0002 μM (100 ng/mL), and M. smegmatis PLJR962-control-gRNA strain (triangles) (c and d) without (gray line) and with (black line) ATc 0.0002 μM (100 ng/mL), and with a final concentration of linezolid of 0.001 µM (0.5 μg/mL) (a), and with a final concentration of rifampicin of 0.03 μM (0.8 μg/mL) (b), and (20 μg/mL) of kanamycin. A significant difference was observed in the linezolid and rifampicin concentrations in M. smegmatis PLJR962-eccD3-gRNA strain without or with ATc from 20 to 27 hours. An unpaired two-tailed Student’s t-test was used and p < 0.01 (**) were obtained (S8 Table and MDdb Science Gateway at http://md-db.org with entry ID 690005 in-vitro data). M. smegmatis mc2 155 wild type growth curve were included in the inner graph. Each experiment was performed in technical triplicates showing the average data with the standard deviation.